Application | Comment | Organism |
---|---|---|
drug development | the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster | Foot-and-mouth disease virus |
drug development | the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster | Transmissible gastroenteritis virus |
drug development | the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster | Hepatovirus A |
drug development | the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster | Severe acute respiratory syndrome-related coronavirus |
drug development | the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster | Norwalk virus |
drug development | the conserved key site of the enzyme may serve as attractive target for the design of broad-spectrum antivirals for multiple viruses in the supercluster | Human calicivirus Hu/NLV/GII/MD145-12/1987/US |
Crystallization (Comment) | Organism |
---|---|
purified recombinant enzyme bound to inhibitor GC376, X-ray diffraction structure determination and analysis at 2.25 A resolution, molecular replacement | Transmissible gastroenteritis virus |
purified recombinant enzyme free and bound to inhibitor (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid, X-ray diffraction structure determination and analysis at 1.50 and 1.65 A resolution, respectively, molecular replacement | Norwalk virus |
Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | - |
Foot-and-mouth disease virus | |
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | - |
Hepatovirus A | |
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US | |
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | - |
Norwalk virus | |
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | - |
Severe acute respiratory syndrome-related coronavirus | |
(2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | - |
Transmissible gastroenteritis virus | |
additional information | efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview | Foot-and-mouth disease virus | |
additional information | efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview | Hepatovirus A | |
additional information | efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview | Human calicivirus Hu/NLV/GII/MD145-12/1987/US | |
additional information | efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview | Norwalk virus | |
additional information | efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview | Severe acute respiratory syndrome-related coronavirus | |
additional information | efficiency of inhibitors in inhibition of virus replication, quantitative realtime PCR expression analysis, overview | Transmissible gastroenteritis virus | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | - |
Foot-and-mouth disease virus | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | - |
Hepatovirus A | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | - |
Norwalk virus | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | - |
Severe acute respiratory syndrome-related coronavirus | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | - |
Transmissible gastroenteritis virus | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | - |
Foot-and-mouth disease virus | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | - |
Hepatovirus A | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | - |
Norwalk virus | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | - |
Severe acute respiratory syndrome-related coronavirus | |
N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | - |
Transmissible gastroenteritis virus | |
rupintrivir | - |
Foot-and-mouth disease virus | |
rupintrivir | - |
Hepatovirus A | |
rupintrivir | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US | |
rupintrivir | - |
Norwalk virus | |
rupintrivir | - |
Severe acute respiratory syndrome-related coronavirus | |
rupintrivir | - |
Transmissible gastroenteritis virus |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Foot-and-mouth disease virus | - |
FMDV | - |
Hepatovirus A | - |
HAV | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US | - |
Noro virus strain MD145 | - |
Norwalk virus | Q83883 | - |
- |
Severe acute respiratory syndrome-related coronavirus | - |
SARS-CoV | - |
Transmissible gastroenteritis virus | P0C6V2 | TGEV | - |
Transmissible gastroenteritis virus Purdue | P0C6V2 | TGEV | - |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
Dabcyl-APAKQLLN-Edans + H2O | - |
Foot-and-mouth disease virus | Dabcyl-APAKQ + LLN-Edans | - |
? | |
Dabcyl-GLRTQSFS-Edans + H2O | - |
Hepatovirus A | Dabcyl-GLRTQ + SFS-Edans | - |
? | |
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O | - |
Transmissible gastroenteritis virus | Dabcyl-KTSAVLQ + SGFRKME-EDANS | - |
? | |
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O | - |
Severe acute respiratory syndrome-related coronavirus | Dabcyl-KTSAVLQ + SGFRKME-EDANS | - |
? | |
Dabcyl-KTSAVLQSGFRKME-EDANS + H2O | - |
Transmissible gastroenteritis virus Purdue | Dabcyl-KTSAVLQ + SGFRKME-EDANS | - |
? | |
Edans-DFHLQGP-Dabcyl + H2O | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US | Edans-DFHLQ + GP-Dabcyl | - |
? | |
Edans-DFHLQGP-Dabcyl + H2O | truncated substrate | Norwalk virus | Edans-DFHLQ + GP-Dabcyl | - |
? |
Synonyms | Comment | Organism |
---|---|---|
3C protease | - |
Foot-and-mouth disease virus |
3C protease | - |
Hepatovirus A |
3C protease | - |
Severe acute respiratory syndrome-related coronavirus |
3C protease | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US |
3C-like protease | - |
Foot-and-mouth disease virus |
3C-like protease | - |
Transmissible gastroenteritis virus |
3C-like protease | - |
Hepatovirus A |
3C-like protease | - |
Severe acute respiratory syndrome-related coronavirus |
3C-like protease | - |
Norwalk virus |
3C-like protease | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US |
3cLpro | - |
Foot-and-mouth disease virus |
3cLpro | - |
Transmissible gastroenteritis virus |
3cLpro | - |
Hepatovirus A |
3cLpro | - |
Severe acute respiratory syndrome-related coronavirus |
3cLpro | - |
Norwalk virus |
3cLpro | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US |
3Cpro | - |
Foot-and-mouth disease virus |
3Cpro | - |
Hepatovirus A |
3Cpro | - |
Severe acute respiratory syndrome-related coronavirus |
3Cpro | - |
Human calicivirus Hu/NLV/GII/MD145-12/1987/US |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Foot-and-mouth disease virus |
37 | - |
assay at | Transmissible gastroenteritis virus |
37 | - |
assay at | Hepatovirus A |
37 | - |
assay at | Severe acute respiratory syndrome-related coronavirus |
37 | - |
assay at | Norwalk virus |
37 | - |
assay at | Human calicivirus Hu/NLV/GII/MD145-12/1987/US |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
6 | - |
assay at | Transmissible gastroenteritis virus |
6 | - |
assay at | Severe acute respiratory syndrome-related coronavirus |
7 | - |
assay at | Hepatovirus A |
8 | - |
assay at | Foot-and-mouth disease virus |
8 | - |
assay at | Norwalk virus |
8 | - |
assay at | Human calicivirus Hu/NLV/GII/MD145-12/1987/US |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.00049 | - |
pH 8.0, 37°C, recombinant enzyme | Norwalk virus | (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | |
0.00055 | - |
pH 8.0, 37°C, recombinant enzyme | Foot-and-mouth disease virus | N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | |
0.00061 | - |
pH 8.0, 37°C, recombinant enzyme | Foot-and-mouth disease virus | N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | |
0.00064 | - |
pH 8.0, 37°C, recombinant enzyme | Norwalk virus | N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | |
0.0007 | - |
pH 8.0, 37°C, recombinant enzyme | Human calicivirus Hu/NLV/GII/MD145-12/1987/US | rupintrivir | |
0.00082 | - |
pH 6.0, 37°C, recombinant enzyme | Transmissible gastroenteritis virus | (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | |
0.00083 | - |
pH 8.0, 37°C, recombinant enzyme | Norwalk virus | rupintrivir | |
0.00096 | - |
pH 8.0, 37°C, recombinant enzyme | Human calicivirus Hu/NLV/GII/MD145-12/1987/US | (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | |
0.00099 | - |
pH 6.0, 37°C, recombinant enzyme | Transmissible gastroenteritis virus | N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | |
0.00116 | - |
pH 8.0, 37°C, recombinant enzyme | Foot-and-mouth disease virus | (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | |
0.00118 | - |
pH 8.0, 37°C, recombinant enzyme | Human calicivirus Hu/NLV/GII/MD145-12/1987/US | N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | |
0.00155 | - |
pH 6.0, 37°C, recombinant enzyme | Transmissible gastroenteritis virus | N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | |
0.00287 | - |
pH 8.0, 37°C, recombinant enzyme | Norwalk virus | N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | |
0.00348 | - |
pH 6.0, 37°C, recombinant enzyme | Severe acute respiratory syndrome-related coronavirus | N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | |
0.00402 | - |
pH 8.0, 37°C, recombinant enzyme | Human calicivirus Hu/NLV/GII/MD145-12/1987/US | N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | |
0.00421 | - |
pH 8.0, 37°C, recombinant enzyme | Foot-and-mouth disease virus | rupintrivir | |
0.00435 | - |
pH 6.0, 37°C, recombinant enzyme | Severe acute respiratory syndrome-related coronavirus | (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | |
0.00466 | - |
pH 6.0, 37°C, recombinant enzyme | Severe acute respiratory syndrome-related coronavirus | N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | |
0.0426 | - |
pH 8.0, 37°C, recombinant enzyme | Hepatovirus A | N2-[(benzyloxy)carbonyl]-N-[(2S)-3,4-dioxo-1-(2-oxopyrrolidin-3-yl)-4-(propan-2-ylamino)butan-2-yl]-L-leucinamide | |
0.05 | - |
above, pH 8.0, 37°C, recombinant enzyme | Hepatovirus A | rupintrivir | |
0.05 | - |
above, pH 8.0, 37°C, recombinant enzyme | Hepatovirus A | N2-[(benzyloxy)carbonyl]-N-[(2S)-1-oxo-3-(2-oxopyrrolidin-3-yl)propan-2-yl]-L-leucinamide | |
0.05 | - |
above, pH 8.0, 37°C, recombinant enzyme | Hepatovirus A | (2S)-2-([N-[(benzyloxy)carbonyl]-L-leucyl]amino)-1-hydroxy-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonic acid | |
0.05 | - |
above, pH 6.0, 37°C, recombinant enzyme | Transmissible gastroenteritis virus | rupintrivir | |
0.05 | - |
above, pH 6.0, 37°C, recombinant enzyme | Severe acute respiratory syndrome-related coronavirus | rupintrivir |